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Abstract 
 
BRCA1 (breast cancer 1, early onset) mutations 
confer a high risk of breast and ovarian cancer. Most 
of BRCA1 cancer-predisposing mutations originate 
truncated proteins, but missense mutations have 
been also detected in familial breast and ovarian 
cancer patients. These variants are rare and their role 
in cancer predisposition is often difficult to ascertain. 
In the present work I studied the molecular 
mechanisms affected in human cells by two BRCA1 
missense variants, M1775R and A1789T, both located 
in the second BRCT domain. These variants have 
been isolated from familial breast cancer patients and 
their effect on cell transcriptome has been previously 
investigated in yeast cells. Here I compared the 
expression profiles of HeLa cells transfected with one 
or the other variant and HeLa cells transfected with 
BRCA1 wild-type. 
Microarray data analysis was performed by three 
comparisons: M1775R versus wild-type 
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(M1775RvsWT-contrast), A1789T versus wild-type 
(A1789TvsWT-contrast) and the mutated BRCT 
domain versus wild-type (MutvsWT-contrast), 
obtained by considering the two variants as a whole. I 
found 201 differentially expressed genes in 
M1775RvsWT-contrast, 313 in A1789TvsWT-contrast 
and 173 in MutvsWT-contrast. Most of these genes 
participate in cell processes that are often 
deregulated in cancer, such as cell cycle progression 
and DNA damage response and repair. These results 
represent the first molecular evidence of the 
pathogenetic role of M1775R, already known by 
functional studies, and give support to a similar role 
for A1789T, first hypothesized based on yeast cell 
experiments. 
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1. Introduction 
 
1.1 BRCA1 and breast cancer 
 
BRCA1 (breast cancer 1, early onset) has been the 
first breast cancer susceptibility gene to be cloned 
(Hall, et al. 1990; Miki, et al. 1994). Along with 
BRCA2 (breast cancer 2, early onset) it is the most 
important disease-associated gene for inherited 
breast cancer. It acts as a tumor suppressor gene 
whose truncating or inactivating germline mutations 
confer a cumulative risk of breast cancer of up to 
80%. BRCA1 germline mutations also cause a risk of 
30-40% of developing ovarian cancer (O'Donovan and 
Livingston 2010). From an histopathological point of 
view, BRCA1 germline mutation carriers usually 
develop high grade Invasive Ductal Carcinomas of No 
Special Type, negative for Estrogen receptor, 
Progesterone receptor and Receptor tyrosine-protein 
kinase erbB-2 (triple negative). In addition, in 
approximately 15% of sporadic breast cancers there 
is loss of nuclear BRCA1 expression, mainly due to 
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epigenetic inactivation or post-transcriptional 
downregulation (Vargas, et al. 2011). 
 
 
1.2 BRCA1 in the cell cycle control  
 
In eukaryotic cells, following DNA damage, cell 
cycle checkpoints are activated to arrest cells at 
certain stage during cell cycle, giving them enough 
time to repair damaged DNA before resuming cell 
cycle progression (Latif, et al. 2001). Cell cycle 
checkpoints are critical for the maintenance of 
genomic integrity as they prevent cells from 
duplication of damaged DNA and passage of it to 
daughter cells. Consistently, dysfunction of proteins 
involved in cell cycle checkpoints often results in 
genomic instability and tumorigenesis (Dasika, et al. 
1999). According to the different stages in which they 
function, cell cycle checkpoints can be categorized 
into G1/S, S-phase and G2/M checkpoints. BRCA1 is 
involved in all of these checkpoints activations. 
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1.2.1 BRCA1 in the G1/S checkpoint 
The G1/S checkpoint is defective in BRCA1-
depleted cells. BRCA1 is indeed required for TP53 
(tumor protein p53) phosphorylation mediated by 
ATM/ATR (ataxia telangiectasia mutated and ataxia 
telangiectasia and Rad3 related) in response to DNA 
damage by ionizing or ultraviolet irradiation (Fabbro, 
et al. 2004). This phosphorylation of TP53 leads to 
cell cycle arrest through the activation of the 
promoter of CDKN1A (cyclin-dependent kinase 
inhibitor 1A) (el-Deiry, et al. 1994). BRCA1 has also 
been shown to increase TP53-mediated activation of 
CDKN1A promoter (Chai, et al. 1999; Zhang, et al. 
1998) 
 
1.2.2 BRCA1 in the S-phase checkpoint 
BRCA1 is specifically required for the S-phase 
checkpoint mediated by ATM in response to ionizing 
irradiation (Xu, et al. 2002). In addition, BRCA1 may 
also regulate ATM activation following DNA damage in 
S phase, as it interacts and colocalize with the MRN 
complex (MRE11A/RAD50/NBN: meiotic 
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recombination 11 homolog A (S. cerevisiae), nibrin, 
RAD50 homolog (S. cerevisiae)) (Zhong, et al. 1999), 
which directly activates ATM (Lee and Paull 2004). 
Evidence has also been presented that BRCA1 is 
involved in the ATR-mediated S-phase checkpoint 
activated by stalled replication forks, which can be 
induced by treatment of cells with UV or hydroxyurea 
(Tibbetts, et al. 2000). Both BRCA1-ATM and BRCA1-
ATR interactions produce the phosphorylation of 
BRCA1 on specific Ser/Thr residues (Tibbetts, et al. 
2000; Xu, et al. 2002).  
 
1.2.3 BRCA1 in the G2/M checkpoint 
The phosphorylation of BRCA1 by ATM is required 
for cell cycle arrest in G2 induced by ionizing 
irradiation (Xu, et al. 2001). In addition, loss of 
BRCA1 abolishes the G2/M checkpoint activation, as 
BRCA1 regulates CHEK1 (CHK1 checkpoint homolog 
(S. pombe)) kinase activity during G2/M checkpoint 
activation (Yu and Chen 2004). 
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1.3 BRCA1 in DNA repair 
 
In response to DNA damage, different DNA repair 
processes utilize different repair machineries. 
However, the two predominant repair pathways are 
homologous recombination and non-homologous end-
joining. Non-homologous end-joining is the most 
common form of DNA repair in cells and constitutes a 
relatively error-prone type of repair as it functions 
without a template. Homologous recombination 
faithfully repairs damaged DNA as it occurs only 
during S and G2 phase of the cell cycle when sister 
chromatids are present and therefore can be used as 
a template (Jackson 2002). 
BRCA1, along with the MRN complex and other 
tumor suppressors and DNA damage repair proteins, 
forms a super complex called BASC (BRCA1 Brca1 
Associated genome Surveillance Complex). The BASC 
coordinates multiple activities related to the 
maintenance of genomic integrity, having an 
important function in DNA damage sensing as well as 
in DNA repair (Wang, et al. 2000). In particular, 
BRCA1, the MRN complex and RBBP8 (retinoblastoma 
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binding protein 8) form a complex that directly 
partecipates in DNA double-strand break repair 
mediated by homologous recombination (Chen, et al. 
2008). 
In addition, BRCA1 has been reported to stimulate 
the base excision repair mechanism by inducing the 
activity of key enzymes of this pathway (Saha, et al. 
2010). 
 
1.4 BRCA1 and global heterocromatin 
state 
 
BRCA1 deficiency leads to global DNA 
hypomethylation and chromatin abnormalities related 
to cancer. Consistently, it has been shown that 
DNMT1 (DNA (cytosine-5-)-methyltransferase 1), the 
methylation maintenance enzyme, is a transcriptional 
target of BRCA1 (Shukla, et al. 2010). 
The most recent hypothesis on BRCA1 concerns a 
role in maintaining global heterochromatin integrity. 
It has been proved that BRCA1 deficiency disrupts 
gene silencing at the tandemly repeated DNA regions, 
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probably through the loss of ubiquitylation of histone 
H2A (Zhu, et al. 2011). 
 
1.5 BRCA1 protein structure 
 
BRCA1 consists of different functional domains: a 
N-terminal RING finger domain, two nuclear 
localization signals, a “SQ” cluster, a branched DNA 
binding domain and a C-terminal domain containing 
two BRCT (BRCA1 C-Terminus) repeats (Linger and 
Kruk 2010). The RING domain of BRCA1 has E3 
ubiquitin ligase activity and facilitates protein 
ubiquitination, which occurs when BRCA1 
heterodimerizes with BARD1 (BRCA1 associated RING 
domain 1) (Baer and Ludwig 2002). BRCT repeats 
have been found in many other proteins that regulate 
DNA damage response and have a crucial role for 
their function (Callebaut and Mornon 1997). BRCT 
repeats have been also described as phosphopeptide-
interacting motifs, facilitating the assembly of DNA 
damage signaling complexes following checkpoint 
kinases activation (Rodriguez, et al. 2003). 
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Consistently, the BRCT repeats of BRCA1 have been 
found to be essential for its targeting to sites of DNA 
damage, due to the BRCT-mediated interaction of 
BRCA1 with other proteins involved in DNA repair 
(Wang, et al. 2007). BRCT domains are also involved 
in the transcriptional activity of BRCA1 and the 
second BRCT repeat (aa 1760-1863) is critical for the 
activation of the CDKN1A promoter (Chai, et al. 
1999). Finally, a recent paper reported that BRCA1 
tumor suppression depends on BRCT phosphoprotein 
binding (Shakya, et al. 2011). 
Due to the relevance of this region for BRCA1 
function, the study of mutations located in this region 
appears of particular interest. 
 
1.6 BRCA1 mutations 
 
A complete list of the mutations detected in 
BRCA1 is reported in the BIC (Breast Cancer 
Information Core) database 
(http://research.nhgri.nih.gov/bic/). Most of the risk-
associated BRCA1 variants are frameshift or nonsense 
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mutations that result in a truncated protein. However, 
missense mutations associated with breast cancer risk 
have also been reported. Some of them have not 
been studied or even completely characterized 
because of their rarity and/or the difficulty of 
attributing functional significance to this type of 
mutation. 
 
1.7 Aim of the present work 
 
Aim of this work was to investigate the effects on 
human cell transcriptome of two BRCA1 missense 
variants, M1775R and A1789T, both located within 
the second BRCA1 BRCT domain and isolated from 
familial breast cancers. In a previous work we 
examined the expression profiles induced by these 
two mutations in yeast cells (Di Cecco, et al. 2009). 
We found alterations of molecular mechanisms critical 
for cell proliferation control and genome integrity, 
suggestive of a putative role of these two variants in 
breast cancer pathogenesis. Here, I compared the 
expression profiles of HeLa cells transfected with one 
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or the other BRCA1 variant with that of HeLa cells 
transfected with BRCA1 wild-type.  
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2. Materials and methods 
 
2.1 BRCA1 missense variants  
 
Both BRCA1 variants are located within the second 
BRCT domain and, while M1775R has widely been 
described as deleterious (Kawai, et al. 2002; Miki, et 
al. 1994; Nikolopoulos, et al. 2007; Olopade, et al. 
2003; Varma, et al. 2005; Williams and Glover 2003), 
A1789T has been studied only by our group. In yeast 
cells both these mutations reverted the growth 
suppression (small colony) phenotype, but only 
M1775R induced homologous recombination (Caligo, 
et al. 2009). In HeLa cells A1789T significantly 
altered the non-homologous end-joining activity as 
compared to BRCA1 wild-type (Guidugli, et al. 2011). 
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2.2 HeLa cells transfection 
 
Five aliquots of the same clone of HeLa G1 cells 
were transiently transfected with the pcDNA3-
BRCA1wild-type vector, five with the pcDNA3-BRCA1-
M1775R derivative vector and five with the pcDNA3-
BRCA1-A1789T derivative vector as described by 
Guidugli et al. [Guidugli et al., 2011]. 
Twenty-four hours after transfection, cells were 
washed twice in PBS 1X, pelleted and immediately 
used to extract RNA or proteins. The increased 
expression of BRCA1 was assessed by Western Blot 
analysis as indicated below. 
 
2.3 Microarray  
 
Gene expression was investigated by Whole 
Human Genome Oligo Microarrays 4x44k G4112F 
(Agilent Technologies, Palo Alto, CA, USA) containing 
4 arrays with 45220 60-mer oligonucleotide probes 
representing 34392 known and 6608 unknown human 
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transcripts. A reference design was adopted using as 
reference a pool of all the RNA samples from the wild-
type clones. Non-reference samples were labeled with 
Cy3 and the reference sample with Cy5. 
Total RNA was extracted and DNase purified with 
PerfectPure RNA Cultured Cell Kit (5 PRIME) 
(Eppendorf, Hamburg, Germany). All RNAs, measured 
by NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Inc. Wilmington, Del, USA), displayed a 
260/280 OD ratio > 1.9. The RNA integrity was 
verified by 1.2% agarose-formaldehyde gel 
electrophoresis. 
Total RNA samples were amplified and labeled 
with the Quick-Amp Labeling kit (Agilent 
Technologies, Palo Alto, CA, USA). One hundred µl of 
In Situ Hybridisation Kit Plus mix (Agilent 
Technologies, Palo Alto, CA, USA) containing 825 ng 
of Cy3 -labelled aRNA (ranging from 11 to 14 Cy3 
pmoles) and 825 ng of Cy5-labelled aRNA (18 Cy5 
pmoles) were hybridized to each array at 65°C for 17 
h under constant rotation. The arrays were then 
washed 1 min at RT in 6X SSPE, 0.005% TritonX-102; 
1 min at 37°C in 0.06X SSPE, 0.005% Triton X-102; 
30 sec at RT in Acetonitrile solution (Agilent 
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Technologies, Palo Alto, CA, USA) and 30 sec at RT in 
Stabilization and Drying solution (Agilent 
Technologies, Palo Alto, CA, USA). 
 
Microarray images were acquired by the Agilent 
scanner G2565BA and intensity raw data were 
extracted by the software Feature Extraction V10.5 
(Agilent Technologies, Palo Alto, CA, USA). Data 
preprocessing and statistical analysis were performed 
by LIMMA (LInear Model of Microarray Analysis) 
(Smyth 2005) tool. The intensity raw data were 
background-subtracted by the normexp method and 
normalized within-arrays with the LOESS and, for 
each non-reference sample classes, between-arrays 
with the scale methods. 
The contrast matrix was set to evaluate three 
comparisons: M1775R versus wild-type 
(M1775RvsWT-contrast), A1789T versus wild-type 
(A1789TvsWT-contrast) and Mutated BRCT domain 
versus wild-type (MutvsWT-contrast), considering the 
two variants as a whole in the latter case. Statistical 
significance to each gene in each comparison was 
 17 
assigned by B-statistic (Lonnstedt and Speed 2002) 
and only genes with B-statistic>0 were included. 
The pathway analysis was done by Pathway-
Express ((Draghici, et al. 2007) 
http://vortex.cs.wayne.edu/projects.htm). The Gene 
Ontology terms were collected by Onto-Express 
(Khatri, et al. 2002); 
http://vortex.cs.wayne.edu/projects.htm). The 
network of biological interactions among differentially 
expressed genes and relevant biological terms was 
observed by Coremine 
(http://www.coremine.com/medical). 
 
2.4 RT-qPCR 
 
RT-qPCR was performed by the iCycler iQ 
instrument (Biorad, Hercules, CA, USA) and the iQ 
SYBR Green Supermix (Biorad, Hercules, CA, USA). 
Total RNAs were reverse transcribed by the 
QuantiTect Reverse Transcription kit (Qiagen, 
Valencia, CA, USA). PCR primers (listed in Table 1) 
were designed by Beacon Designer 4.0 (Premier 
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Biosoft. International, Palo Alto, CA, USA). RT-qPCR 
experiments were performed according to MIQE 
guidelines (Bustin, et al. 2009). Primer amplification 
efficiency (90%-110%) and correlation coefficient 
(>0.98) were tested. Four housekeeping genes, ACTB 
(actin, beta), HPRT1 (hypoxanthine 
phosphoribosyltransferase 1), TBP (TATA box binding 
protein) and GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), tested for stability by geNorm 
(M<1.5 and V3/4<0.07) (Vandesompele, et al. 2002), 
were used to normalize the differential expression 
values of target genes. The analysis was performed 
considering the variants separately for the 
M1775RvsWT- and the A1789TvsWT- contrasts, but 
as a whole for the MutvsWT-contrast. One-tailed 
Wilcoxon signed rank test was applied to evaluate the 
statistical significance of results adopting a threshold 
of 0.05. 
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2.5 Western Blot 
 
Western Blot was performed as previously 
reported (Guidugli, et al. 2011). 
The expression of BRCA1 protein was assessed 
using the anti-BRCA1 monoclonal antibody Ab4 
diluted 1:100 (Calbiochem-Novabiochem Corp., 
Gibbstown, NJ, USA) that recognizes aa 1005–1313 in 
the exon 11 of BRCA1.  
The level of protein expression was analyzed for: 
GPR56 (anti-GPR56 rabbit polyclonal antibody H-93: 
sc-99089, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA, dilution 1:1000 ), MRE11A (anti-
MRE11A mouse monoclonal antibody 18: sc-135992, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, 
dilution 1:500); NFKB1 (anti-NFKB1 mouse 
monoclonal antibody E-10: sc-8414, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA, dilution 
1:100 ) and PML (anti-PML mouse monoclonal IgG2b 
clone 36.1-104, Upstate Biotechnology, Inc., 
Waltham, MA, USA, dilution 1:500). 
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Gene 
Symbol 
Gene Name Primer Sequences 
Housekeepin
g genes     
ACTB actin, beta F: 5'-AACTGGAACGGTGAAGGTGAC-3' R: 5'-GACTTCCTGTAACAACGCATCTC-3' 
HPRT1 
hypoxanthine 
phosphoribosyltransferas
e 1 
F: 5'-ACATCTGGAGTCCTATTGACATCG-3' 
R: 5'-TTAAACAACAATCCGCCCAAAGG-3' 
GAPDH 
glyceraldehyde-3-
phosphate 
dehydrogenase 
F: 5'-GTGAAGGTCGGAGTCAACG-3' 
R: 5'-GGTGAAGACGCCAGTGGACTC-3' 
TBP TATA box binding protein F: 5'-GGTGTTGTGAGAAGATGGATGTTG-3' R: 5'-CCAGATAGCAGCACGGTATGAG-3' 
Target genes     
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
F: 5'-ACTAGGCGGTTGAATGAGAGGTTC-3' 
R: 5'-CAGGTCTGAGTGTCCAGGAAAGG-3' 
EDN1 endothelin 1 F: 5'-CCAACCATCTTCACTGGCTTCC-3' R: 5'-GTCAGACACAAACACTCCCTTAGG-3' 
EEF1E1 
eukaryotic translation 
elongation factor 1 
epsilon 1 
F: 5'-TGCGGGAGGTTCTTGTTCTG-3' 
R: 5'-CTGTTAGACTTGGACCATTGTTTG-3' 
GPR56 G protein-coupled receptor 56 
F: 5'-CTACAGCCGAAGAATGTGACTC-3' 
R: 5'-GCAGAAGCAGGATGTTTGGG-3' 
MRE11A 
MRE11 meiotic 
recombination 11 
homolog A (S. 
cerevisiae) 
F: 5'-GATGATGAAGTCCGTGAGGCTATG-3' 
R: 5'-TGTTGGTTGCTGCTGAGATGC-3' 
NFKB1 
nuclear factor of kappa 
light polypeptide gene 
enhancer in B-cells 1 
F: 5'-CCGTTGGGAATGGTGAGGTC-3' 
R: 5'-TTGAGAATGAAGGTGGATGATTGC-3' 
OBFC2B 
oligonucleotide/oligosacc
haride-binding fold 
containing 2B 
F: 5'-GACGATGTTGGCAATCTG-3' 
R: 5'-TGGCTCACTGAAGTTAGG-3' 
PML promyelocytic leukemia F: 5'-CCAAGGCAGTCTCACCAC-3' R: 5'-TTCGGCATCTGAGTCTTCC-3' 
SOD2 superoxide dismutase 2, mitochondrial 
F: 5'-GGTGTCCAAGGCTCAGGTTG-3' 
R: 5'-GTGCTCCCACACATCAATCCC-3' 
 
Table 1: Primer sequences. 
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3. Results 
 
3.1 Microarray results 
 
The M1775RvsWT-contrast showed 201 
differentially expressed genes, 129 downregulated 
and 72 upregulated, while the A1789TvsWT-contrast 
showed 313 differentially expressed genes, 128 
downregulated and 185 upregulated and the 
MutvsWT-contrast showed 173 differentially 
expressed genes, 100 downregulated and 73 
upregulated. Twenty-four of these genes were 
differentially expressed with the same fold change 
direction in all the comparisons (Fig. 1). 
Complete information about the microarray 
experiments and results can be retrieved from the 
ArrayExpress database at the European 
Bioinformatics Institute (EBI) 
(http://www.ebi.ac.uk/arrayexpress/) by using the 
following accession number: E-MTAB-761. 
 22 
 
 
Fig. 1: Venn diagram showing the numbers of 
differentially expressed genes shared by the three 
comparisons. 
 
Pathway analysis mapped 40 genes in 58 KEGG 
pathways for M1775RvsWT-contrast, 52 genes in in 
62 KEGG pathways for A1789TvsWT-contrast and 27 
genes in 37 KEGG pathways for MutvsWT-contrast. In 
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all the three comparisons many pathways with high 
impact factor were involved in cancer. 
Twenty-eight pathways were in common among 
the three comparisons as indicated in Fig. 2. 
 
Fig. 2: Venn diagram showing the numbers of 
pathways shared by the three comparisons. 
 
Coremine identified 3594 and 2045 genes linked 
to biological terms concerning “Cell Proliferation” and 
“DNA damage and repair” processes, respectively. 
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Intersections among these two lists and the three lists 
of differentially expressed genes are shown in Fig. 3. 
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a) 
 
b) 
 
Fig. 3: Intersections among the lists of differentially 
expressed genes and “Cell Proliferation” (a) and “DNA 
damage and repair” (b). 
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3.2 Microarray data validation 
 
The differential expression of nine transcripts 
(Table 1) among those identified by microarray 
analysis was validated by RT-qPCR: CDKN1A (cyclin-
dependent kinase inhibitor 1A (p21, Cip1)), EDN1 
(endothelin 1), EEF1E1 (eukaryotic translation 
elongation factor 1 epsilon 1), GPR56 (G protein-
coupled receptor 56), MRE11A (MRE11 meiotic 
recombination 11 homolog A (S. cerevisiae)), NFKB1 
(nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1), OBFC2B 
(oligonucleotide/oligosaccharide-binding fold 
containing 2B), PML (promyelocytic leukemia) and 
SOD2 (superoxide dismutase 2, mitochondrial) (Fig. 
4). 
The differential expression was consistently 
confirmed for all the thirteen validations. 
The differential expression of GPR56, MRE11A, 
NFKB1 and PML proteins was also confirmed by 
Western Blot analysis. 
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Fig. 4: Microarray and RT-qPCR log2-Fold changes for 
the 9 validated genes. All the log2-Fold changes are 
statistically significant (p-value<0.05). 
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4. Discussion 
 
Aim of this study was to analyze the effects on 
human cell transcriptome of two BRCA1 missense 
variants located in the BRCT domain of the protein, 
M1775R and A1789T. Specifically, the gene 
expression profiles of HeLa cells transfected with one 
or the other variant were compared with that of HeLa 
cells transfected with BRCA1 wild-type. We also 
analyzed the combined outcome of the two BRCT 
mutations in comparison to the wild-type. To this 
purpose, three different statistical contrasts were 
performed: M1775R versus wild-type (M1775RvsWT-
contrast), A1789T versus wild-type (A1789TvsWT-
contrast) and Mutated BRCT domain versus wild-type 
(MutvsWT-contrast) (see Materials and methods). 
Pathway analysis retrieved many pathways involved 
in cancer onset and progression as well as linked to 
specific tumors. Ontological and data-mining analyses 
highlighted three functional categories: cell cycle 
regulation, apoptosis and DNA damage response and 
repair, typically deregulated in cancer cells. Cell cycle 
and apoptosis deregulation leads to aberrant cell 
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proliferation, while an impaired DNA damage 
response and repair causes genomic instability. All 
these processes are closely connected, as apoptosis, 
constituting a defense from anomalous proliferation, 
is linked to cell cycle block and is activated in 
response to DNA damage.  
 
 
4.1 Aberrant cell proliferation 
 
Cancer cells abnormally proliferate. In these cells 
occurs overexpression of mitogenic factors, such as 
cell cycle positive regulators, as well as impairment of 
mechanisms ensuring correct cell division, including 
apoptosis, as reviewed by Strobl et al., Zafonte et al. 
and Vermeulen et al., among many (Strobl, et al. 
1995; Vermeulen, et al. 2003; Zafonte, et al. 2000). 
In our data, a considerable number of 
differentially expressed genes is strictly linked to cell 
proliferation (Table 2). 
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Biological 
Process 
Gene 
Symbol Gene Name Contrast 
log2 (Fold 
Change) 
Cell cycle 
arrest 
impairment 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) M1775RvsWT -0.3066647 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 
M1775RvsWT 
MutvsWT 
-0.3728651 
-0.3190284 
SMAD3 SMAD family member 3 
A1789TvsWT 
M1775RvsWT 
MutvsWT 
-0.2675322 
-0.4286813 
-0.3196246 
CCND1 cyclin D1 A1789TvsWT 0.3622112 
PML promyelocytic leukemia M1775RvsWT -0.3045759 
RUVBL1 RuvB-like 1 (E. coli) M1775RvsWT -0.3028029 
TXNIP thioredoxin interacting protein A1789TvsWT -0.3985633 
RASSF1 Ras association (RalGDS/AF-6) domain family member 1 A1789TvsWT -0.2766158 
Cell 
proliferation 
enhancement 
FOS FBJ murine osteosarcoma viral oncogene homolog 
A1789TvsWT 
M1775RvsWT 
MutvsWT 
0.4515777 
0.4020256 
0.4365775 
DUSP1 dual specificity phosphatase 1 
A1789TvsWT 
M1775RvsWT 
MutvsWT 
0.3844494 
0.7606655 
0.5060076 
DUSP2 dual specificity phosphatase 2 MutvsWT 0.5408689 
EDN1 endothelin 1 M1775RvsWT MutvsWT 
0.4442705 
0.3212824 
SKP1 S-phase kinase-associated protein 1 A1789TvsWT 0.3353208 
ZWILCH 
Zwilch, kinetochore 
associated, homolog 
(Drosophila) 
A1789TvsWT 0.2508541 
GPR56 G protein-coupled receptor 56 
A1789TvsWT 
M1775RvsWT 
MutvsWT 
-0.3453577 
-0.3310188 
-0.3407359 
Apoptosis 
blocking 
NFKB1 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 
M1775RvsWT -0.2522979 
TNFRSF10B 
tumor necrosis factor 
receptor superfamily, 
member 10b 
M1775RvsWT -0.247568 
DYRK2 
dual-specificity tyrosine-(Y)-
phosphorylation regulated 
kinase 2 
M1775RvsWT -0.282513 
PLEKHF1 
pleckstrin homology domain 
containing, family F (with 
FYVE domain) member 1 
MutvsWT -0.2374774 
 
Table 2: Genes linked to aberrant cell proliferation. 
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4.1.1 Cell cycle arrest impairment 
CDKN1A, downregulated by M1775R, is a main 
effector of cell cycle arrest in response to DNA 
damage and a promoter of apoptosis (Cazzalini, et al. 
2010). Its expression is usually activated by BRCA1 
(Chai, et al. 1999).  
Cell cycle can be also arrested by the cooperation 
of CDKN1A with CEBPA (Harris, et al. 2001) that is in 
turn downregulated by M1775R. 
CDKN1A expression is normally activated also by 
SMAD3, a known transcription factor that acts as an 
effector of the TGF-beta pathway (Moustakas and 
Kardassis 1998; Pardali, et al. 2005), downregulated 
in all the three comparisons. The overexpression of 
SMAD3 in a breast cancer cell line causes cell cycle 
arrest (Tian, et al. 2003), while in SMAD3-/- 
mammary epithelial cells, both TGF-beta-induced 
growth inhibition and apoptosis are lost (Kohn, et al. 
2010).  
SMAD3 also contributes to the 3-indole-induced 
G1 arrest in cancer cells (Huang, et al. 2011) and its 
inhibition depends on CCND1-CDK4 (cyclin-dependent 
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kinase 4) action in breast cancer cells overexpressing 
CCND1 (Zelivianski, et al. 2010), upregulated by 
A1789T. The loss or reduction of BRCA1 expression, 
moreover, significantly reduces the TGF-beta induced 
activation of SMAD3 in breast cancer cells (Li, et al. 
2009).  
Considering this, the downregulation of CDKN1A, 
CEBPA and SMAD3 might constitute a key element in 
carcinogenesis predisposition caused by the 
considered variants. The downregulation of other four 
genes further supports the hypothesis of a deficiency 
in cell cycle arrest: PML (in M1775RvsWT) which 
codifies for a phosphoprotein localized in nuclear 
bodies, involved in TP53 (tumor protein p53) -
mediated cell cycle arrest in G1 (Chan, et al. 1997) as 
well as in recognition and/or processing of DNA 
breaks by recruiting TP53 and MRE11A (Carbone, et 
al. 2002); RUVBL1 (in M1775RvsWT) that encodes a 
highly conserved ATP-dependent DNA helicase which 
is part of chromatin-remodeling complexes and plays 
a role in apoptosis and DNA repair (Ikura, et al. 2000; 
Jha, et al. 2008; Makino, et al. 1998); TXNIP (in 
A1789TvsWT) that encodes a transcriptional repressor 
acting as a tumor suppressor, as its transfection 
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induces cell-cycle arrest in G0/G1 phase and is 
downregulated in human tumors (Han, et al. 2003) 
and RASSF1 (in A1789TvsWT), a tumor suppressor 
that blocks cell cycle progression by inhibiting CCND1 
accumulation. It is epigenetically inactivated at high 
frequency in a variety of tumors, including breast 
cancer (Burbee, et al. 2001; Shivakumar, et al. 
2002). 
 
4.1.2 Cell proliferation enhancement 
The transcription factor FOS, upregulated in all the 
three comparisons, is a well known protooncogene 
that positively regulates cell cycle progression 
(Shaulian and Karin 2001) and is induced in human 
breast cancer cell cultures, being part of the 
mitogenic signal transduction typical of these cells, as 
reviewed by Strobl et al. (Strobl, et al. 1995).  
DUSP1, upregulated in all the three comparisons, 
and DUSP2, upregulated in MutvsWT, belong to a 
subfamily of tyrosine phosphatases that regulate the 
activity of Mitogen-Activated Protein Kinases 
(MAPKs). MAPKs are key effectors for cell growth 
control and survival in physiological and pathological 
conditions, including cancer. DUSPs have therefore 
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been proposed as potential targets for anticancer 
drugs, as reviewed by Nunes-Xavier et al. (Nunes-
Xavier, et al. 2011). DUSP1 inhibits apoptosis in 
human mammary epithelial and breast carcinoma 
cells (Small, et al. 2004). Moreover, DUSP1 
expression was found upregulated in many breast 
cancers (Wang, et al. 2003). The overexpression of 
DUSP2 in ovarian cancers has been correlated with 
poor outcome (Givant-Horwitz, et al. 2004). 
EDN1, upregulated by M1775R and in MutvsWT, is 
a vasoconstrictor that has also co-mitogenic activity, 
potentiating the growth factors effects. Altered EDN1 
signalling is involved in carcinogenesis by modulating 
cell survival and promoting invasiveness (Bagnato 
and Rosanò 2008).  
SKP1, upregulated by A1789T, is a component of 
the SCF complex that mediates the ubiquitination of 
cell cycle proteins promoting cell cycle progression 
(Bassermann and Pagano 2010). 
ZWILCH, upregulated by A1789T, is an essential 
component of the mitotic checkpoint that prevents 
cells from exiting mitosis prematurely (Kops, et al. 
2005; Williams and Glover 2003).  
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GPR56, downregulated in all the three contrasts, 
is a G protein-coupled receptor involved in adhesion 
processes that participates in cytoskeletal signaling, 
cellular adhesion and tumor invasion. It is 
downregulated in melanoma cell lines, while its 
overexpression suppresses tumor growth and 
metastasis (Xu, et al. 2006).  
 
4.1.3 Apoptosis blocking 
NFKB1, downregulated by M1775R, is a pleiotropic 
transcription factor involved in many biological 
processes like inflammation, immunity, 
differentiation, cell growth, tumorigenesis and 
apoptosis. Whether NFKB activation contributes or not 
to cancer is controversial, as reviewed by Shishodia 
and Aggarwal (Shishodia and Aggarwal 2004), as it 
regulates the expression of both antiapoptotic (Rayet 
and Gélinas 1999) and proapoptotic genes (Kühnel, et 
al. 2000; Shetty, et al. 2005). 
Interestingly, TNFRSF10B, that was in turn 
downregulated by M1775R, is one of the proapoptotic 
genes upregulated by NFKB (Shetty, et al. 2005). 
TNFRSF10B is one of the two apoptosis-activating 
receptors binding the receptor TNFSF10 (tumor 
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necrosis factor (ligand) superfamily, member 10) 
(Sheridan, et al. 1997). Upon binding, an adaptor 
protein called FADD (Fas(TNFRSF6)-Associated via 
Death Domain) is recruited to the death receptors, 
forming a signaling complex that leads to apoptosis 
through caspases activation (Suliman, et al. 2001). 
The downregulation of both NFKB1 and TNFRSF10B in 
our data suggests an inhibition of TNF-mediated 
apoptosis. 
Two other proapoptotic genes, DYRK2 and 
PLEKHF1, resulted as downregulated in our data. 
DYRK2, downregulated by M1775R, is a protein 
kinase that regulates TP53 to induce apoptosis in 
response to DNA damage downstream of ATM (Taira, 
et al. 2007), and PLEKHF1, downregulated in 
MutvsWT, is a recently discovered lysosome-
associated protein that activates caspase-independent 
apoptosis (Chen, et al. 2005) by interacting with the 
TP53 transactivation domain (Li, et al. 2007).  
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4.2 Genomic instability 
 
An improper reaction to genotoxic stress causes 
genomic instability, leading to tumorigenesis. 
Deficiencies in DNA damage signaling and repair 
pathways are thus fundamental to the etiology of 
cancer (Khanna and Jackson 2001). 
A number of differentially expressed genes takes 
part in genotoxic stress response. Among these 
genes, some were downregulated causing an increase 
in genomic instability, while others were upregulated 
(Table 3). Many tumors, including BRCA1-deficient 
breast cancers, show an overexpression of genes 
linked to DNA repair that correlates with 
chemoresistance and poor prognosis (Martin, et al. 
2007; Saviozzi, et al. 2009). Moreover, an increased 
nuclear staining of DNA repair proteins has been 
recently observed in tissue sections of breast cancers 
carrying the M1775R mutation, suggesting a new 
mechanism of tumorigenesis involving an enhance of 
homologous recombination (Dever, et al. 2011). 
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Biological 
Process 
Gene 
Symbol Gene Name Contrast 
log2 (Fold 
Change) 
DNA damage 
response and 
repair 
downregulation 
EEF1E1 eukaryotic translation elongation factor 1 epsilon 1 A1789TvsWT -0.4309041 
SMC1A structural maintenance of chromosomes 1A 
A1789TvsWT 
MutvsWT 
-0.2754507 
-0.2640263 
PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme A1789TvsWT -0.4286825 
AHNAK AHNAK nucleoprotein 
A1789TvsWT 
M1775RvsWT 
MutvsWT 
-0.3988113 
-0.3103867 
-0.3940570 
SOD2 superoxide dismutase 2, mitochondrial 
M1775RvsWT 
MutvsWT 
-0.3376169 
-0.2502831 
DNA damage 
response and 
repair 
upregulation 
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) A1789TvsWT 0.3293561 
TERF1 telomeric repeat binding factor (NIMA-interacting) 1 MutvsWT 0.2790907 
OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A M1775RvsWT 0.3666172 
OBFC2B oligonucleotide/oligosaccharide-binding fold containing 2B 
A1789TvsWT 
MutvsWT 
0.4070777 
0.3417360 
 
Table 3: Genes linked to genomic instability. 
 
4.2.1 DNA damage response and repair 
downregulation 
EEF1E1, downregulated by A1789T, first 
discovered as associated with a macromolecular tRNA 
synthetase complex, is a key factor for ATM/ATR-
mediated TP53 activation in response to DNA damage 
(Park, et al. 2005).  
SMC1A, downregulated by A1789T, encodes an 
evolutionarily conserved chromosomal protein, 
component of the cohesin complex (Sumara, et al. 
2000). It is involved in the ATM/NBN-dependent S-
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phase checkpoint pathway, associating with BRCA1 
and being phosphorylated in response to ionizing 
radiations (Yazdi, et al. 2002). 
PPP1CC, downregulated by A1789T, is the 
catalytic subunit of the gamma isoform of PP1 which 
is a component of a signaling complex, 
PPP1R1A/PPP1R15A/PPP1CC (protein phosphatase 1, 
regulatory (inhibitor) subunit 1A, protein phosphatase 
1, regulatory subunit 15A, protein phosphatase 1, 
catalytic subunit, gamma isozyme) that positively 
regulates apoptosis in response to various stresses, 
including growth arrest and DNA damage (Connor, et 
al. 2001). 
AHNAK, downregulated by A1789T, encodes a 
protein typically repressed in human neuroblastoma 
cell lines and in several other types of tumors 
(Shtivelman, et al. 1992). It firmly binds the LIG4-
XRCC4 (ligase IV, DNA, ATP-dependent and X-ray 
repair complementing defective repair in Chinese 
hamster cells 4) complex on DNA stimulating its 
double-stranded ligation activity (Stiff, et al. 2004). 
SOD2, downregulated by M1775R and in 
MutvsWT, is a member of the iron/manganese 
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superoxide dismutase family that acts as a free 
radical scavenger, thus protecting from oxidative 
damage. It is a candidate tumor suppressor gene as 
the loss of heterozygosity of its region on 
chromosome 6 has been found in about 40% of 
human malignant melanomas (Oberley and Oberley 
1997) and the deletion of chromosome 6 long arm 
has been identified in SV40 transformed human 
fibroblast (Bravard, et al. 1992). In addition, SOD2 
overexpression suppresses the tumorigenicity of 
breast cancer cells (Li, et al. 1995). 
 
4.2.2 DNA damage response and repair 
upregulation 
MRE11A, upregulated by A1789T, encodes a 
component of the BASC that specifically promotes 
non-homologous end-joining (see Introduction) 
(Wang, et al. 2000; Zhang and Powell 2005). The 
nuclease activity of MRE11A is required for non-
homologous end-joining mediated by the MRN 
complex (see Introduction), and, interestingly, BRCA1 
suppresses this activity in vitro (Paull, et al. 2001). 
Interestingly, the A1789T variant altered the non-
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homologous end-joining activity in a functional assay 
(Guidugli, et al. 2011). 
TERF1, upregulated in MutvsWT, is a telomere-
associated protein, member of the telomere 
nucleoprotein complex that interacts with various 
macromolecular complexes including MRN (Kuimov 
2004). 
OBFC2A, upregulated by M1775R, and OBFC2B, 
upregulate by A1789T and in MutvsWT, encode 
single-stranded DNA-binding proteins essential for a 
variety of DNA metabolic processes, including 
replication, recombination and damage detection and 
repair. OBFC2B, in particular, as an early participant 
in DNA damage response, is critical for genomic 
stability (Richard, et al. 2008).  
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5. Concluding remarks 
 
This work was focused on two BRCA1 BRCT 
missense variants, M1775R and A1789T, both isolated 
from familial breast cancers. M1775R has widely been 
described as deleterious (Kawai, et al. 2002; Miki, et 
al. 1994; Nikolopoulos, et al. 2007; Olopade, et al. 
2003; Varma, et al. 2005; Williams and Glover 2003), 
while A1789T has been studied only by our group. In 
yeast cells both of these mutations reverted the 
growth suppression (small colony) phenotype (Caligo, 
et al. 2009), showing a characteristic behaviour of 
cancer-predisposing missense BRCA1 BRCT mutations 
(Coyne, et al. 2004). M1775R also induced 
homologous recombination in yeast cells (Caligo, et 
al. 2009). In HeLa cells A1789T significantly altered 
the non-homologous end-joining activity as compared 
to BRCA1 wild-type (Guidugli, et al. 2011). 
As previously observed in yeast cells (Di Cecco, et 
al. 2009), also in human cells the BRCA1 variants 
M1775R and A1789T affect the expression of many 
genes critical for cell proliferation and genome 
integrity maintenance. Our results represent a 
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molecular confirm of the pathogenetic role of M1775R 
and give support to a similar role of A1789T that we 
first hypothesized on the basis of the experiments in 
yeast cells. 
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